Mechanism of action of dopaminergic agents in Parkinson's disease

Neurology

Volumn 50, Issue 6 SUPPL.6, 1998, Pages

  Koller, William C ^a   Rueda, Miguel G ^b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b Ctro de Especialidades Neurologicas   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; AMINO ACID; AMINO ACID DECARBOXYLASE; BENSERAZIDE; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE; CATECHOL METHYLTRANSFERASE INHIBITOR; DOMPERIDONE; DOPAMINE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; FLUDROCORTISONE ACETATE; INDOMETACIN; LEVODOPA; MIDODRINE; RECEPTOR SUBTYPE; SELEGILINE; TRIMETHOBENZAMIDE;

DECARBOXYLATION; DRUG MECHANISM; DYSKINESIA; HUMAN; NAUSEA; NIGRONEOSTRIATAL SYSTEM; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SUBSTANTIA NIGRA; VOMITING;

EID: 0031811153     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.50.6_suppl_6.s11     Document Type: Review

References (29)

1. Hornykiewicz O. Dopamine (3-hydroxytyramine) and brain function. Pharmacol Rev 1966;18:925-962.
2. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N Engl J Med 1988;318:876-880.
3. Horne MK, Cheng CH, Wooten GF. The cerebral metabolism of 1-dihydroxyphenylalanine: an autoradiographic and biochemical study. Pharmacology 1974;28:12-26.
4. Hornykiewicz O. The mechanism of action of L-dopa in Parkinson's disease. Life Sci 1974;15:1249-1259.
5. Nutt JG. Pharmacokinetics and pharmacodynamics of levodopa. In: Koller WC, ed. Handbook of Parkinson's disease. New York: Marcel Dekker, 1992:411-732.
6. Djaldetti R, Baron J, Ziv I, Melamed E. Gastric emptying in Parkinson's disease: patients with and without response fluctuations. Neurology 1996;46:1051-1054.
7. Lloyd KG, Davidson L, Hornykiewicz O. The neurochemistry of Parkinson's disease: effect of L-dopa therapy. J Pharmacol Exp Ther 1975;195:453-464.
8. Melamed E, Hefti F, Wurtman RJ. Nonaminergic striatal neurons convert exogenous L-dopa to dopamine in parkinsonism. Ann Neurol 1980;8:558-563.
9. Trugman JM, James CL, Wooten GF. D1/D2 dopamine receptor stimulation by L-DOPA. Brain 1991;114:1429-1440.
10. Steiger MJ, Quinn NA. Levodopa-based therapy. In: Koller WC, ed. Handbook of Parkinson's disease. New York: Marcel Dekker, 1992:319-416.
11. Poewe W, Granata R. Pharmacologic treatment of Parkinson's disease. In: Watts RL, Koller WC, eds. Movement disorders: neurologic principles and practice. New York: McGraw-Hill 1992:201-221.
12. Tanner CM, Goetz CG, Klawans HL. Autonomic nervous system dysfunction. In: Koller WC, ed. Handbook of Parkinson's disease. New York: Marcel Dekker, 1992:185-215.
13. Riley DE, Lang AE. The spectrum of levodopa-related fluctuations in Parkinson's disease. Neurology 1993;43:1459-1464.
14. Nutt JG. On-off phenomenon: relation to levodopa pharmacokinetics and pharmacodynamics. Ann Neurol 1987;22:535-540.
15. Mouradian MM, Chase TN. Central mechanisms and levodopa response fluctuations in Parkinson's disease. Clin Neuropharmacol 1988;11:378-385.
16. Chase TN, Engber TM, Mouradian MM. Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson's disease. Neurology 1994;44(suppl 6): S15-18.
17. Papa SM, Engber TM, Kask AM, Chase TN. Motor fluctuations in levodopa-treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res 1994;662:69-74.
18. Bravi D, Mouradian MM, Roberts JW, Davis TL, Sohn YH Chase TN. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms. Ann Neurol 1994; 36:27-31.
19. Mouradian MM, Juncos JL, Fabbrini G, Schlegel J, Bartko JJ, Chase TN. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, part II. Ann Neurol 1988;24: 372-378.
20. Mouradian MM, Heuser IJ, Baronti F, Fabbrini G, Juncos JL Chase TN. Pathogenesis of dyskinesias in Parkinson's disease. Ann Neurol 1989;25:523-526.
21. Leenders KL, Palmer AJ, Quinn N, et al. Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry 1986;49:853-860.
22. Varhagen Metman L, Locatelli ER, Bravi D, Mouradian MM, Chase TN. Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications. Neurology 1997;48: 369-372.
23. Fabbrini G, Mouradian MM, Juncos JL, Schlegel J, Mohr E, Chase TN. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, part I. Ann Neurol 1988;24: 366-371.
24. Nutt JG, Woodward WR, Carter JH, Gancher ST. Effect of long-term therapy on the pharmacodynamics of levodopa: relation to on-off phenomenon. Arch Neurol 1992;42:1123-1130.
25. Koller WC, Silver DE, Lieberman A. Algorithm for the management of Parkinson's disease. Neurology 1994;44(suppl 10): 527-533.
26. Sage JL, Mark MH. The rationale for continuous dopaminergic stimulation in patients with Parkinson's disease. Neurology 1992;42(suppl 1):33-38.
27. Baron MS, Virek JL, Bakry RA, et al. Treatment of advanced Parkinson's disease by posterovential GP's pallidotomy. 1-year results of a pilot study. Ann Neurol 1996; 40:355-366.
28. Stellins G, Goetz C. Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology 1995;45:669-672.
29. Freidman JH, Lannon MC. Clozapine in the treatment of psychosis in Parkinson's disease. Neurology 1989;39:1219-1221.